Could a blood vessel blocker boost esophageal cancer treatment?

NCT ID NCT06281886

Completed Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding the drug apatinib to standard chemotherapy and radiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will receive either the standard treatment or the standard treatment plus apatinib. The study tracks how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Apatinib (a drug that blocks blood vessel growth to tumors)
What this could lead to: If successful, adding apatinib could improve how long patients live without their cancer growing, offering a new option for hard-to-treat esophageal cancer.
What could go wrong: This is a mid-stage trial with only 170 people, so results may not apply to everyone. Apatinib can cause side effects like high blood pressure or bleeding, and the added benefit over standard therapy is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EFFICACY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EFFICACY ESOPHAGEAL SQUAMOUS CELL CARCINOMA TOXICITY

Contacts and locations

Locations

Sun yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.